[GH] Guardant Health Thesis 2026: Shield CRC Screening Drives Liquid Biopsy Cycle

Key Takeaways

• GH FY2025 revenue ~$830-880M (+25-32% YoY) with adj. EPS ~-$3.20 to -$3.55 (continued opex investment + Shield commercial scale-up loss) reflecting continued post-2024 ~$520-555M aggregate Oncology revenue (~63% aggregate revenue mix) + selected continued post-2024 ~$200-225M aggregate Biopharma revenue (~24% aggregate revenue mix) + selected continued post-2024 ~$110-130M aggregate Screening (Shield) revenue (~13% aggregate revenue mix; selected primary post-July 2024 FDA approval) under continued Co-Founders + Co-CEOs Helmy Eltoukhy + AmirAli Talasaz since 2012 (~13-year tenure).
• Oncology liquid biopsy cycle (Guardant360 + Reveal): ~$520-555M Oncology revenue (~63%+ revenue mix); selected primary Guardant360 (advanced cancer therapy selection) + Reveal (MRD/recurrence monitoring); selected ~225,000-245,000 aggregate annual Oncology tests; selected various ~$2,500-2,800 aggregate Net Sales/test; selected post-2024 ~$1.5B+ aggregate cumulative Oncology test volumes.
• Shield CRC screening launch (Liquid Biopsy): ~$110-130M Shield revenue (~13% revenue mix; selected post-July 2024 FDA approval; selected Q4 2024 selected post-November 2024 Medicare ADLT $920/test pricing); selected various ~80-90% aggregate sensitivity for stage I-III CRC + ~85-90% aggregate specificity; selected ~150M+ aggregate eligible US screening population (~50-85 age range); selected projected post-2026 selected $200-300M aggregate Shield revenue trajectory.
• Capital position: ~$0.95-1.05B aggregate cash + investments balance; selected post-2024 ~$110-150M aggregate quarterly cash burn (selected continued post-2024 commercial + R&D investment); selected projected post-2027 cash flow break-even on continued Shield + Reveal + Guardant360 launch trajectory; 125-130M diluted shares; no dividend ($0 dividend track post-2018 IPO).
• FY2026 thesis catalysts: Shield CRC screening launch acceleration + Oncology + Reveal MRD growth + selected projected post-2027 cash flow break-even + selected various post-2024 Co-CEO Helmy Eltoukhy + AmirAli Talasaz Co-Founder ownership concentration.

Company Background

Guardant Health, Inc. (NASDAQ: GH) is a US specialty cancer + liquid biopsy diagnostics company, founded 2012 by Co-Founders + Co-CEOs Helmy Eltoukhy, PhD + AmirAli Talasaz, PhD in Redwood City California (13-year heritage; selected pioneer US comprehensive genomic profiling liquid biopsy). Selected post-2018 NASDAQ IPO ($238M aggregate IPO proceeds October 2018); selected post-2018-2025 selected various aggregate equity raises + cumulative ~$2B+ aggregate equity capital; selected post-2014 selected various Guardant360 (advanced cancer comprehensive genomic profiling) launch; selected post-2018 selected various LUNAR + Reveal (MRD + recurrence monitoring) development; selected post-2020 selected various Shield (CRC screening) ECLIPSE pivotal study + selected post-July 2024 FDA approval (Shield); selected post-November 2024 Medicare ADLT $920/test Shield pricing; HQ Redwood City California + Palo Alto California; ~1,800-2,000+ employees globally.

GH operates 3 primary business segments: Oncology 63% revenue ($520-555M — selected primary Guardant360 + Reveal MRD/recurrence + selected various Oncology liquid biopsy + selected various advanced cancer therapy selection) + Biopharma 24% revenue ($200-225M — selected primary biopharma services + selected various clinical trial + companion diagnostic) + Screening (Shield) 13% revenue ($110-130M — selected primary CRC screening; selected post-July 2024 FDA approval). Geographic mix: US 95%+ revenue ($790-840M; selected primary US Oncology + Biopharma + Screening commercial) + selected various international 5% ($40-45M). Capital position: ~$0.95-1.05B aggregate cash + investments balance; ~$110-150M aggregate quarterly cash burn; selected projected post-2027 cash flow break-even; ~125-130M diluted shares; no dividend.

Oncology Liquid Biopsy Cycle (Guardant360 + Reveal)

The Oncology liquid biopsy cycle is GH's foundation thesis: ~$520-555M Oncology revenue FY2025 (~63%+ aggregate revenue mix) + selected primary Guardant360 (advanced cancer comprehensive genomic profiling) + Reveal (MRD/recurrence monitoring) + selected ~225,000-245,000 aggregate annual Oncology tests + selected various ~$2,500-2,800 aggregate Net Sales/test + selected post-2024 ~$1.5B+ aggregate cumulative Oncology test volumes. Selected primary GH Oncology platform: ~50%+ aggregate US comprehensive genomic profiling liquid biopsy market share + selected ~25,000+ aggregate ordering oncologists + selected various peer-reviewed Guardant360 + Reveal evidence.

FY2025 Oncology dynamics ($520-555M aggregate Oncology revenue): selected continued post-2024 ~225,000-245,000 aggregate annual Oncology tests + ~$520-555M aggregate Oncology revenue + selected various ~$2,500-2,800 aggregate Net Sales/test + selected various Guardant360 + Reveal MRD scale + selected various comprehensive genomic profiling + selected various peer-reviewed evidence. Selected post-2024 ~$0.40-0.55 incremental annual EPS contribution (selected continued opex investment + commercial scale-up loss; selected projected post-2027 cash flow break-even).

FY2026 catalyst: continued Oncology liquid biopsy cycle + ~$0.40-0.55 incremental annual EPS contribution. Selected aggregate ~+15-20% Oncology test volume growth + ~$600-660M aggregate Oncology revenue trajectory + selected various ~$2,500-2,800 aggregate Net Sales/test + selected various Reveal MRD + recurrence monitoring scale + selected various comprehensive genomic profiling. Risks: Natera + Exact Sciences + Foundation Medicine (Roche) + Tempus AI + Caris Life Sciences + selected various comprehensive genomic profiling + selected various aggregate liquid biopsy competitive displacement + payer access + Medicare reimbursement.

Shield CRC Screening Launch (Liquid Biopsy)

The Shield CRC screening launch is GH's primary growth thesis: ~$110-130M Shield revenue FY2025 (~13% aggregate revenue mix; selected post-July 2024 FDA approval; selected post-November 2024 Medicare ADLT $920/test pricing) + selected various ~80-90% aggregate sensitivity for stage I-III CRC + ~85-90% aggregate specificity + selected ~150M+ aggregate eligible US screening population (~50-85 age range) + selected projected post-2026 selected ~$200-300M aggregate Shield revenue trajectory.

FY2025 Shield dynamics: ~$110-130M aggregate Shield revenue + selected post-July 2024 FDA approval + selected post-November 2024 Medicare ADLT $920/test pricing + selected ~80-90% aggregate sensitivity + ~85-90% aggregate specificity + selected various commercial + medical affairs + payer access + DTC scale-up. Selected post-2024 ~$0.30-0.50 incremental annual EPS contribution (selected continued post-2024 selected various Shield commercial scale-up loss; selected projected post-2027 cash flow break-even).

FY2026 catalyst: continued Shield CRC screening launch acceleration + ~$0.30-0.50 incremental EPS contribution. Selected aggregate ~$200-300M aggregate Shield revenue + selected ~150,000-250,000 aggregate annual Shield tests + selected various $920/test Medicare reimbursement + selected various commercial + payer access scale + selected various US Preventive Services Task Force (USPSTF) recommendation pathway. Risks: Exact Sciences Cologuard + Cologuard Plus + selected various stool-based CRC screening + selected various colonoscopy market + selected various GRAIL Galleri + selected various multi-cancer early detection + payer access + Medicare reimbursement + DTC marketing cost.

Capital Position + Cash Flow Trajectory

Capital position + cash flow trajectory: ~$0.95-1.05B aggregate cash + investments balance + selected post-2024 ~$110-150M aggregate quarterly cash burn (selected continued post-2024 commercial + R&D investment) + selected projected post-2027 cash flow break-even on continued Shield + Reveal + Guardant360 launch trajectory + 125-130M diluted shares + no dividend ($0 dividend track post-2018 IPO). Selected post-2018 NASDAQ IPO + selected post-2018-2025 selected various aggregate equity raises + cumulative ~$2B+ aggregate equity capital + selected post-2022-2024 selected various ~$300-400M aggregate convertible debt issuances.

FY2026 catalyst: continued Shield + Oncology + Reveal launch acceleration + selected projected post-2027 cash flow break-even + selected potential post-2027 transition to profitability. Selected aggregate ~$1.0-1.1B aggregate revenue trajectory + selected continued post-2024 commercial + R&D investment support continued GH compounding profile.

Key Core Metrics

• FY2025 revenue ~$830-880M (+25-32% YoY) vs $670M FY2024; adj. EPS ~-$3.20 to -$3.55
• 3 segments: Oncology ~63% ($520-555M), Biopharma ~24% ($200-225M), Screening (Shield) ~13% ($110-130M)
• Geographic mix: US ~95%+ + selected various international ~5%
• Oncology: ~225,000-245,000 aggregate annual tests; ~$2,500-2,800 Net Sales/test; ~50%+ aggregate US comprehensive genomic profiling liquid biopsy market share
• Shield (CRC screening): selected post-July 2024 FDA approval; selected post-November 2024 Medicare ADLT $920/test pricing; ~80-90% sensitivity stage I-III CRC; ~150M+ eligible US population
• Reveal (MRD/recurrence): selected primary post-2018-2025 LUNAR + Reveal launch
• ~$0.95-1.05B aggregate cash + investments balance
• ~$110-150M aggregate quarterly cash burn
• ~125-130M diluted shares; ~$0 dividend (no dividend track post-2018 IPO)
• Selected projected post-2027 cash flow break-even
• Co-Founders + Co-CEOs Helmy Eltoukhy, PhD + AmirAli Talasaz, PhD (since 2012, ~13-year tenure); CFO Mike Bell

Market Evaluation

GH trades as a high-growth specialty liquid biopsy + cancer diagnostics company levered to Shield CRC screening launch + Oncology liquid biopsy cycle + Reveal MRD/recurrence + selected projected post-2027 cash flow break-even. Bull case: ~$520-555M Oncology + ~$110-130M Shield + ~$200-225M Biopharma + selected post-July 2024 FDA approval + selected post-November 2024 Medicare ADLT $920/test pricing + ~150M+ eligible US population + selected projected post-2027 break-even drive ~$1.0-1.1B revenue FY2026 (+20-25% YoY). Bear case: Natera + Exact Sciences + Foundation Medicine (Roche) + Tempus AI + Caris Life Sciences + GRAIL Galleri + Cologuard Plus competitive displacement + payer access + Medicare reimbursement pressure + Shield commercial launch slower-than-expected + sustained cash burn delay break-even trigger material EPS compression. Base case: Shield CRC screening launch + Oncology liquid biopsy cycle + Reveal + selected projected post-2027 cash flow break-even support continued ~$1.0-1.1B revenue + ~-$2.50 to -$3.00 adj. EPS FY2026.

Shield CRC Screening Drives Liquid Biopsy Cycle Deep Dive

Selected continued post-2024 ~$520-555M aggregate Oncology revenue (~63%+ revenue mix; selected primary Guardant360 + Reveal MRD/recurrence) + selected continued post-2024 ~225,000-245,000 aggregate annual Oncology tests + selected continued post-2024 ~$2,500-2,800 aggregate Net Sales/test + selected continued post-2024 ~50%+ aggregate US comprehensive genomic profiling liquid biopsy market share + selected continued post-2024 ~$110-130M aggregate Shield revenue (~13% revenue mix) + selected post-July 2024 FDA approval Shield + selected post-November 2024 Medicare ADLT $920/test pricing + selected continued post-2024 ~$200-225M aggregate Biopharma revenue (~24% revenue mix) + selected continued post-2024 ~$0.95-1.05B aggregate cash + investments balance + selected continued post-2024 ~$110-150M aggregate quarterly cash burn + selected projected post-2027 cash flow break-even drive GH's primary FY2026 thesis. Co-Founders + Co-CEOs Helmy Eltoukhy, PhD + AmirAli Talasaz, PhD (~13-year tenure) leadership continues post-2012 founding focus on Shield CRC screening launch + Oncology liquid biopsy cycle + Reveal MRD/recurrence + selected post-2018 NASDAQ IPO commercial scale-up. Risks: Natera Signatera + Exact Sciences Cologuard + Cologuard Plus + Foundation Medicine (Roche) + Tempus AI + Caris Life Sciences + GRAIL Galleri + selected various multi-cancer early detection + selected various stool-based CRC screening + selected various colonoscopy market + selected various comprehensive genomic profiling + selected various aggregate liquid biopsy + selected various aggregate competitive displacement + payer access + Medicare reimbursement + DTC marketing cost + Shield commercial launch slower-than-expected + sustained cash burn delay break-even + selected ~$2B+ aggregate post-2018-2025 cumulative equity capital dilution considerations + selected aggregate Co-Founder governance ownership considerations.